Dexniguldipine (BioDeep_00000008553)

Main id: BioDeep_00000749326

 

human metabolite blood metabolite


代谢物信息卡片


3-((4,4-Diphenyl-1-piperidinyl)propyl)-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride

化学式: C36H39N3O6 (609.2839)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(C(C(=C(N1)C)C(=O)OCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
InChI: InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3

描述信息

D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators
D000970 - Antineoplastic Agents

同义名列表

11 个代谢物同义名

3-((4,4-Diphenyl-1-piperidinyl)propyl)-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride; 3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-Methyl-5-(3-(4,4-diphenyl-1-piperidinyl)propyl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate; Niguldipine hydrochloride; Niguldipine hydrobromide; Niguldipine fumarate; Niguldipine maleate; Dexniguldipine; NIGULDIPINE; DNIG; Niguldipine



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 9 ABCB1, ADRA1A, CACNA1A, CALCA, DHPS, ENO2, HPGDS, SLC9A1, SRI
Endoplasmic reticulum membrane 1 SRI
Mitochondrion membrane 1 ABCG2
Nucleus 3 ADRA1A, CACNA1A, FOS
cytosol 8 ADRA1A, DHPS, ENO2, FOS, HPGDS, NCAM1, PRKCQ, SRI
mitochondrial membrane 1 ABCG2
nucleoplasm 6 ABCG2, ADRA1A, FOS, HPGDS, SLC9A1, SRI
RNA polymerase II transcription regulator complex 1 FOS
Cell membrane 9 ABCB1, ABCG2, ADRA1A, ADRA1D, ADRB3, CACNA1A, ENO2, NCAM1, SLC9A1
lamellipodium 1 SLC9A1
Multi-pass membrane protein 9 ABCB1, ABCG2, ADRA1A, ADRA1D, ADRB3, CACNA1A, CACNA1I, RHO, SLC9A1
Synapse 1 CACNA1A
cell surface 3 ABCB1, NCAM1, SLC9A1
Golgi apparatus 1 RHO
Golgi membrane 2 NCAM1, RHO
neuronal cell body 2 CACNA1A, CALCA
plasma membrane 13 ABCB1, ABCG2, ADRA1A, ADRA1D, ADRB3, CACNA1A, CACNA1I, ENO2, NCAM1, PRKCQ, REN, RHO, SLC9A1
terminal bouton 1 CALCA
Membrane 10 ABCB1, ABCG2, CACNA1A, CACNA1I, ENO2, NCAM1, REN, RHO, SLC9A1, SRI
apical plasma membrane 3 ABCB1, ABCG2, SLC9A1
basolateral plasma membrane 1 SLC9A1
caveola 1 ADRA1A
extracellular exosome 5 A2ML1, ABCB1, ENO2, SLC9A1, SRI
endoplasmic reticulum 1 FOS
extracellular space 4 A2ML1, CALCA, ENO2, REN
perinuclear region of cytoplasm 1 SLC9A1
intercalated disc 1 SLC9A1
mitochondrion 1 SLC9A1
intracellular membrane-bounded organelle 2 ADRA1A, HPGDS
Single-pass type I membrane protein 1 NCAM1
Secreted 3 A2ML1, CALCA, REN
extracellular region 4 A2ML1, CALCA, NCAM1, REN
hippocampal mossy fiber to CA3 synapse 1 CALCA
centriolar satellite 1 PRKCQ
ciliary membrane 1 RHO
photoreceptor inner segment 2 ENO2, RHO
photoreceptor outer segment 1 RHO
Nucleus membrane 1 ADRA1A
nuclear membrane 1 ADRA1A
external side of plasma membrane 1 NCAM1
T-tubule 2 SLC9A1, SRI
perikaryon 1 ENO2
Z disc 1 SRI
apical part of cell 1 REN
cell-cell junction 1 RHO
Apical cell membrane 2 ABCB1, ABCG2
Membrane raft 2 ABCG2, SLC9A1
focal adhesion 1 SLC9A1
sarcoplasmic reticulum 1 SRI
collagen-containing extracellular matrix 1 NCAM1
receptor complex 1 ADRB3
chromatin 1 FOS
cell projection 1 CACNA1A
Cell projection, cilium, photoreceptor outer segment 1 RHO
brush border membrane 1 ABCG2
sperm midpiece 1 RHO
Basolateral cell membrane 1 SLC9A1
Lipid-anchor, GPI-anchor 1 NCAM1
Endomembrane system 1 SRI
Membrane, caveola 1 ADRA1A
monoatomic ion channel complex 1 CACNA1A
Golgi-associated vesicle membrane 1 RHO
nuclear matrix 1 FOS
voltage-gated calcium channel complex 2 CACNA1A, CACNA1I
Photoreceptor inner segment membrane 1 RHO
Sarcoplasmic reticulum membrane 1 SRI
immunological synapse 1 PRKCQ
neuronal dense core vesicle 1 CALCA
aggresome 1 PRKCQ
protein-DNA complex 1 FOS
external side of apical plasma membrane 2 ABCB1, ABCG2
photoreceptor outer segment membrane 1 RHO
sperm head plasma membrane 1 RHO
photoreceptor disc membrane 1 RHO
transcription factor AP-1 complex 1 FOS
phosphopyruvate hydratase complex 1 ENO2
rod photoreceptor outer segment 1 RHO
[Isoform 4]: Cell membrane 1 NCAM1
[Isoform 6]: Secreted 1 NCAM1
cation-transporting ATPase complex 1 SLC9A1


文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Mia Niklasson, Gianluca Maddalo, Zuzana Sramkova, Ercan Mutlu, Shimei Wee, Petra Sekyrova, Linnéa Schmidt, Nicolas Fritz, Ivar Dehnisch, Gregorios Kyriatzis, Michaela Krafcikova, Brittany B Carson, Jennifer M Feenstra, Voichita D Marinescu, Anna Segerman, Martin Haraldsson, Anna-Lena Gustavsson, Lars G J Hammarström, Annika Jenmalm Jensen, Lene Uhrbom, A F Maarten Altelaar, Sten Linnarsson, Per Uhlén, Lukas Trantirek, C Theresa Vincent, Sven Nelander, Per Øyvind Enger, Michael Andäng. Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses. Cancer research. 2017 04; 77(7):1741-1752. doi: 10.1158/0008-5472.can-16-2274. [PMID: 28087597]
  • Kinga K Borowicz, Zdzislaw Kleinrok, Stanislaw J Czuczwar. Niguldipine impairs the protective activity of carbamazepine and phenobarbital in amygdala-kindled seizures in rats. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2002 Jun; 12(3):225-33. doi: 10.1016/s0924-977x(02)00027-5. [PMID: 12007674]
  • J K Schröder, S Kasimir-Bauer, S Seeber, M E Scheulen. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia. Journal of cancer research and clinical oncology. 2000 Feb; 126(2):111-6. doi: 10.1007/s004320050019. [PMID: 10664252]
  • J F Beck, F Buchholz, W R Ulrich, R Boer, K H Sanders, D Niethammer, V Gekeler. Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309-068, a newly designed pyridine derivative. Cancer letters. 1998 Jul; 129(2):157-63. doi: 10.1016/s0304-3835(98)00094-9. [PMID: 9719457]
  • K K Borowicz, M Gasior, Z Kleinrok, S J Czuczwar. Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice. European journal of pharmacology. 1997 Mar; 323(1):45-51. doi: 10.1016/s0014-2999(97)00020-4. [PMID: 9105875]
  • V Nuessler, M E Scheulen, R Oberneder, M Kriegmair, K J Goebel, F Rathgeb, W Wurst, K Zech, W Wilmanns. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. European journal of medical research. 1997 Feb; 2(2):55-61. doi: . [PMID: 9085015]
  • J H Schellens, W Van de Vrie, W J Loos, H J Kolker, J Verweij, G Stoter, N M Durante, A M Eggermont. Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats. Cancer chemotherapy and pharmacology. 1997; 41(1):48-52. doi: 10.1007/s002800050706. [PMID: 9443613]
  • R Chess-Williams, C R Chapple, F Verfurth, A J Noble, C J Couldwell, M C Michel. The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor. British journal of pharmacology. 1996 Nov; 119(6):1093-100. doi: 10.1111/j.1476-5381.1996.tb16009.x. [PMID: 8937710]
  • G Stubauer, D Obendorf. Determination of trace levels of niguldipine in urine and blood by adsorptive stripping voltammetry at the hanging mercury drop electrode. The Analyst. 1996 Mar; 121(3):351-6. doi: 10.1039/an9962100351. [PMID: 8729657]
  • W Van de Vrie, J H Schellens, W J Loss, H J Kolker, J Verwey, G Stoter, N M Durante, A M Eggermont. Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model. Journal of cancer research and clinical oncology. 1996; 122(7):403-8. doi: 10.1007/bf01212879. [PMID: 8690750]
  • L Goedhals, W R Bezwoda, R P Abratt, F Rathgeb, K J Goebel, W Wurst. Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug. International journal of clinical pharmacology and therapeutics. 1995 Dec; 33(12):664-9. doi: NULL. [PMID: 8963484]
  • C Ludescher, W Eisterer, W Hilbe, J Hofmann, J Thaler. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. British journal of haematology. 1995 Nov; 91(3):652-7. doi: 10.1111/j.1365-2141.1995.tb05362.x. [PMID: 8555069]
  • D R Ferry, P J Malkhandi, M A Russell, D J Kerr. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochemical pharmacology. 1995 Jun; 49(12):1851-61. doi: 10.1016/0006-2952(94)00517-p. [PMID: 7598747]
  • D R Blue, D W Bonhaus, A P Ford, J R Pfister, N A Sharif, I A Shieh, R L Vimont, T J Williams, D E Clarke. Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat. British journal of pharmacology. 1995 May; 115(2):283-94. doi: 10.1111/j.1476-5381.1995.tb15875.x. [PMID: 7670730]
  • T A Esbenshade, A Hirasawa, G Tsujimoto, T Tanaka, J Yano, K P Minneman, T J Murphy. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells. Molecular pharmacology. 1995 May; 47(5):977-85. doi: NULL. [PMID: 7746284]
  • D Ukena, C Boewer, B Oldenkott, F Rathgeb, W Wurst, K Zech, G W Sybrecht. Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial. Cancer chemotherapy and pharmacology. 1995; 36(2):160-4. doi: 10.1007/bf00689202. [PMID: 7767953]
  • J Drímal, L Bohácik. The effect of photogenerated site-directed free radicals on surface dihydropyridine binding sites identified with photoaffinity probe (-)-[3H]-azidopine on cultured monkey renal cells. Methods and findings in experimental and clinical pharmacology. 1994 Jul; 16(6):397-404. doi: . [PMID: 7530790]
  • J Drímal. Identification of dihydropyridine (DHP) binding sites on cultured monkey renal cells (GMRC) with a photoaffinity probe (-)-[3H]-azidopine. General physiology and biophysics. 1994 Apr; 13(2):137-48. doi: . [PMID: 7528701]
  • M C Michel, R Büscher, T Philipp, O E Brodde. Alpha 1A and alpha 1B-adrenoceptors enhance inositol phosphate generation in rat renal cortex. Naunyn-Schmiedeberg's archives of pharmacology. 1993 Feb; 347(2):180-5. doi: 10.1007/bf00169264. [PMID: 8097282]
  • V Höllt, M Kouba, M Dietel, G Vogt. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochemical pharmacology. 1992 Jun; 43(12):2601-8. doi: 10.1016/0006-2952(92)90149-d. [PMID: 1352973]
  • C A Jackson, M C Michel, P A Insel. Expression of renal alpha 1-adrenergic receptor subtypes in established hypertension. Journal of cardiovascular pharmacology. 1992 Jun; 19(6):857-62. doi: 10.1097/00005344-199206000-00003. [PMID: 1376804]
  • K Zech, R Herzog. Two-dimensional high-performance liquid chromatography at low ng/ml levels of the anti-proliferative agent B859-35 in serum with automated sample clean-up, solid-phase trapping and ultraviolet detection. Journal of chromatography. 1991 Aug; 553(1-2):55-63. doi: 10.1016/s0021-9673(01)88472-7. [PMID: 1787169]
  • M P Drozd, K Gietzen. Effects of the novel dihydropyridine derivative niguldipine on the cytoplasmic free calcium concentration of mouse thymocytes. Biochemical pharmacology. 1990 Sep; 40(5):955-9. doi: 10.1016/0006-2952(90)90479-5. [PMID: 2390115]
  • G Fischer, G Krumpl, N Mayer, W Schneider, G Raberger. Antihypertensive effects of niguldipine-HCl (B 844-39), a new calcium antagonist in dogs. Journal of cardiovascular pharmacology. 1987 Sep; 10(3):268-73. doi: 10.1097/00005344-198709000-00003. [PMID: 2444773]